Węgry - węgierski - OGYÉI (Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézetről)

hospira uk ltd. - remifentanil -

Węgry - węgierski - OGYÉI (Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézetről)

hospira uk ltd. - remifentanil -

Węgry - węgierski - OGYÉI (Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézetről)

hospira uk ltd. - remifentanil -

Unia Europejska - węgierski - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - pemigatinib - cholangiocarcinoma - daganatellenes szerek - pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed  after at least one prior line of systemic therapy.

Unia Europejska - węgierski - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - ceftolozane-szulfát, nátrium-tazobactam - bakteriális fertőzések - szisztémás antibakteriális szerek, - zerbaxa is indicated for the treatment of the following infections in adults:complicated intra abdominal infections;acute pyelonephritis;complicated urinary tract infections;hospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap). figyelembe kell venni hivatalos útmutató a megfelelő használatára az antibakteriális szerek.

Węgry - węgierski - OGYÉI (Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézetről)

octapharma (ip) sprl - humán fibrinogén -

Węgry - węgierski - NÉBIH (Nemzeti Élelmiszerlánc-biztonsági Hivatal)

alpha-vet Állatgyógyászati kft. - m.Á.-szol koncentrátum, ung. hydrophilicum nonionicum, adeps lanae, sol. cons. - kenocs - szarvasmarha, sertés, ló, kutya, macska

Węgry - węgierski - NÉBIH (Nemzeti Élelmiszerlánc-biztonsági Hivatal)

alpha-vet Állatgyógyászati kft. - m.Á.-szol koncentrátum, etanol, 96 %-os - külsoleges oldat - szarvasmarha, sertés, ló, kutya, macska

Unia Europejska - węgierski - EMA (European Medicines Agency)

roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - daganatellenes szerek - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq, mint monoterápia kezelésére felnőtt betegek lokálisan előrehaladott vagy metasztatikus nsclc után előzetes kemoterápia. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq, mint monoterápia kezelésére felnőtt betegek lokálisan előrehaladott vagy metasztatikus nsclc után előzetes kemoterápia. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

Węgry - węgierski - OGYÉI (Országos Gyógyszerészeti és Élelmezés-egészségügyi Intézetről)

ipsen pharma - triptorelin -